publication . Article . 2011

Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.

Tine Gregersen; Henning Grønbæk; Jonas Worsøe; Vincent Schlageter; Søren Laurberg; Klaus Krogh;
Restricted English
  • Published: 01 Jul 2011
Abstract
Abstract Background. Diarrhea is part of the carcinoid syndrome and a significant clinical problem in neuroendocrine tumor (NET) patients. Somatostatin analog (SA) treatment usually alleviates carcinoid diarrhea, but little is known about the objective effects of SA on gastrointestinal transport. Aim. To compare gastrointestinal motility in healthy subjects and NET patients before and during SA treatment. Methods. Twelve NET patients were studied before and during 4 weeks of SA treatment and were compared with 12 healthy controls. Radio-opaque markers were used for the assessment of total gastrointestinal transit time (GITT). Gastric and small intestinal (SI) tr...
Subjects
free text keywords: Gastroenterology, Neuroendocrine tumors, medicine.disease, medicine, Carcinoid syndrome, Gastrointestinal transit time, Motility, Diabetes mellitus, Somatostatin analog, medicine.medical_specialty, Diarrhea, medicine.symptom, Internal medicine, Gastrointestinal transport, Endocrinology, business.industry, business
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2011

Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.

Tine Gregersen; Henning Grønbæk; Jonas Worsøe; Vincent Schlageter; Søren Laurberg; Klaus Krogh;